BRPI0410360A - composições para a sub-regulação da expressão de ccr5 e métodos para seu uso - Google Patents

composições para a sub-regulação da expressão de ccr5 e métodos para seu uso

Info

Publication number
BRPI0410360A
BRPI0410360A BRPI0410360-2A BRPI0410360A BRPI0410360A BR PI0410360 A BRPI0410360 A BR PI0410360A BR PI0410360 A BRPI0410360 A BR PI0410360A BR PI0410360 A BRPI0410360 A BR PI0410360A
Authority
BR
Brazil
Prior art keywords
compositions
methods
ccr5 expression
hiv
composition
Prior art date
Application number
BRPI0410360-2A
Other languages
English (en)
Inventor
Redfield Robert
Davis Anthony Amoroso Charles
Heredia Alonsa
Original Assignee
Univ Maryland Biotech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst
Publication of BRPI0410360A publication Critical patent/BRPI0410360A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES PARA A SUB-REGULAçãO DA EXPRESSãO DE CCR5 E MéTODOS PARA SEU USO". A presente invenção refere-se à sub-regulação da expressão do receptor CCR5 de superfície através da manipulação do ciclo celular em linfócitos ativados pela administração de uma composição que interrompe a fase G1 do ciclo celular, desta forma reduzindo os sítios receptores para a entrada de HIV em células T, e, assim, os efeitos do HIV. Além disto, é descrita uma composição que inclui um agente de interrupção da fase G1 e um agente antiviral, onde a combinação aumenta de forma sinérgica a atividade do agente antiviral.
BRPI0410360-2A 2003-05-16 2004-05-17 composições para a sub-regulação da expressão de ccr5 e métodos para seu uso BRPI0410360A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47145303P 2003-05-16 2003-05-16
PCT/US2004/015681 WO2005001027A2 (en) 2003-05-16 2004-05-17 Compositions for down-regulation of ccr5 expression and methods of use therefor

Publications (1)

Publication Number Publication Date
BRPI0410360A true BRPI0410360A (pt) 2006-08-01

Family

ID=33551427

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410360-2A BRPI0410360A (pt) 2003-05-16 2004-05-17 composições para a sub-regulação da expressão de ccr5 e métodos para seu uso

Country Status (8)

Country Link
US (1) US7863242B2 (pt)
EP (1) EP1627048A4 (pt)
CN (1) CN1805740A (pt)
AU (1) AU2004251228B2 (pt)
BR (1) BRPI0410360A (pt)
CA (1) CA2526122A1 (pt)
RU (1) RU2353357C2 (pt)
WO (1) WO2005001027A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261763B1 (en) * 1995-06-07 2001-07-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
WO2004024683A2 (en) * 2002-09-13 2004-03-25 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR
KR20050057408A (ko) * 2002-09-18 2005-06-16 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제
US7241803B2 (en) * 2002-11-21 2007-07-10 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
WO2008134076A1 (en) * 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US10500274B2 (en) 2008-04-30 2019-12-10 Cytodyn Inc. Methods for reducing viral load in HIV-1 infected patients
AU2015305401A1 (en) * 2014-08-20 2017-03-02 Cytodyn Inc. HIV antibody therapy as treatment substitute

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4812393A (en) * 1992-09-03 1994-03-29 Biochem Pharma Inc. Use of rapamycin in the treatment of aids
DE69305093T2 (de) 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU6761198A (en) * 1998-03-17 1999-10-11 Julianna Lisziwiewicz Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6251874B1 (en) * 1998-03-26 2001-06-26 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
US20030099944A1 (en) 1998-07-31 2003-05-29 Schaffer Priscilla A. Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins
US20030060457A1 (en) 1998-07-31 2003-03-27 Schaffer Priscilla A. Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins
US6098780A (en) 1998-08-07 2000-08-08 Terra Nova Technologies, Inc. Tracking, propulsion and braking system for bridge tripper/hopper car
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU2002245081A1 (en) 2000-12-06 2002-07-16 The Trustees Of The University Of Pennsylvania Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
AU2002242096A1 (en) 2001-02-06 2002-08-19 The University Of Georgia Research Foundation, Inc. Novel compounds and methods for inhibiting/treating hiv infections and aids related symptoms
DE10129028A1 (de) 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
GB0123025D0 (en) 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
AU2002351898A1 (en) * 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
WO2004024683A2 (en) * 2002-09-13 2004-03-25 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR

Also Published As

Publication number Publication date
WO2005001027A2 (en) 2005-01-06
EP1627048A2 (en) 2006-02-22
RU2005139394A (ru) 2006-06-10
US7863242B2 (en) 2011-01-04
AU2004251228A1 (en) 2005-01-06
RU2353357C2 (ru) 2009-04-27
EP1627048A4 (en) 2008-10-15
CN1805740A (zh) 2006-07-19
WO2005001027A3 (en) 2006-01-26
US20060154857A1 (en) 2006-07-13
CA2526122A1 (en) 2005-01-06
AU2004251228B2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AR034518A1 (es) Incremento en la administracion transdermica de un farmaco
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR9805993A (pt) Composição farmacêutica de aerosol.
BR9915285A (pt) Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
BR0015580A (pt) Composições analgésicas contendo buprenorfina
BRPI0512410A (pt) compostos de amido e seu uso como produtos farmacêuticos
BR0111908A (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças
BRPI0510736A (pt) compostos de amido e seu uso como produtos farmacêuticos
BRPI0411555A (pt) composição anestésica para administração tópica compreendendo lidocaìna, prilocaìna e tetracaìna
BRPI0515316A (pt) compostos de imidazoquinolina
BRPI0514116A (pt) artigos absorventes compreendendo um agente modificador de exsudado corpóreo e uma formulação para cuidado da pele
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
BRPI0807544B8 (pt) corpo alongado para injeção parenteral livre de agulha em baixa velocidade de um dispositivo, método para fazer o referido corpo, uso do mesmo e embalagem de droga para uso com um dispositivo de distribuição de droga
BRPI0515600A (pt) formas farmacêuticas opióides tendo cmédia e auc em estado estável proporcionais à dose e cmax de dose única inferior ao proporcional à dose
TR200200981T2 (tr) Farmasötik bileşim terkipleri
MY177591A (en) Nk1 receptor antagonist composition
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
WO2005001027A3 (en) Compositions for down-regulation of ccr5 expression and methods of use therefor
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
DE60133887D1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
PE123899A1 (es) Formulacion que contiene un opioide en combinacion con un agonista alfa-adrenergico y su utilizacion como analgesico
IS6439A (is) Samsetningar til að meðhöndla viðnám gegn háþrýstingslyfjum
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/355, 31/35, 31/33, 31/435, 31/17, 31/385, 31/70; A61P 31/18

Ipc: A61K 31/355 (2011.01), A61K 31/35 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.